– First patient dosing expected in Q3 2023 – – ZONE study to assess ZT-01’s ability to prevent night-time hypoglycemia, a condition for which there are currently no available therapies – TORONTO, April 19, 2023 /PRNewswire/ – Zucara Therapeutics Inc., (“Zucara” or the “Company”) a…